APOE and familial hypercholesterolemia: Although ezetimibe has been shown to reduce atherosclerosis progression mainly through its effect on plasma LDL cholesterol by inhibiting its absorption by the intestine (40, 41), it is possible that ezetimibe may indirectly affect inflammation associated with hypercholesterolemia in apoE−/− mice by reducing LDL cholesterol and subsequently inflammatory modified LDL.